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Cellular growth, function, and protection require proper iron management, and ferritin
plays a crucial role as the major iron sequestration and storage protein. Ferritin
is a 24 subunit spherical shell protein composed of both light (FTL) and heavy
chain (FTH1) subunits, possessing complimentary iron-handling functions and forming
three-fold and four-fold pores. Iron uptake through the three-fold pores is well-defined,
but the unloading process somewhat less and generally focuses on lysosomal
ferritin degradation although it may have an additional, energetically efficient pore
mechanism. Hereditary Ferritinopathy (HF) or neuroferritinopathy is an autosomal
dominant neurodegenerative disease caused by mutations in the FTL C-terminal
sequence, which in turn cause disorder and unraveling at the four-fold pores allowing
iron leakage and enhanced formation of toxic, improperly coordinated iron (ICI).
Histopathologically, HF is characterized by iron deposition and formation of ferritin
inclusion bodies (IBs) as the cells overexpress ferritin in an attempt to address iron
accumulation while lacking the ability to clear ferritin and its aggregates. Overexpression
and IB formation tax cells materially and energetically, i.e., their synthesis and disposal
systems, and may hinder cellular transport and other spatially dependent functions. ICI
causes cellular damage to proteins and lipids through reactive oxygen species (ROS)
formation because of high levels of brain oxygen, reductants and metabolism, taxing
cellular repair. Iron can cause protein aggregation both indirectly by ROS-induced protein
modification and destabilization, and directly as with mutant ferritin through C-terminal
bridging. Iron release and ferritin degradation are also linked to cellular misfunction
through ferritinophagy, which can release sufficient iron to initiate the unique programmed
cell death process ferroptosis causing ROS formation and lipid peroxidation. But IB
buildup suggests suppressed ferritinophagy, with elevated iron from four-fold pore
leakage together with ROS damage and stress leading to a long-term ferroptotic-like
state in HF. Several of these processes have parallels in cell line and mouse models. This
review addresses the roles of ferritin structure and function within the above-mentioned
framework, as they relate to HF and associated disorders characterized by abnormal iron
accumulation, protein aggregation, oxidative damage, and the resulting contributions to
cumulative cellular stress and death.
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INTRODUCTION
Life has evolved incorporating iron as a crucial element in a
number of metabolic processes by utilizing it in biochemical
catalysis, electron transfer, and oxygen transport and storage.
Familiar are the hemeproteins hemoglobin andmyoglobin which
perform the latter two processes, cytochrome-c for electron
transport, and the cytochromes P-450 which perform drug
metabolism. In addition, there are major metabolic pathways
that require non-heme iron enzymes as centers of catalytic
transformation. Neurotransmitter synthesis is intimately
connected with such enzymes, e.g., tryptophan hydroxylase
and tyrosine hydroxylase, which perform the initial reactions
transforming tryptophan and tyrosine into neurotransmitters.
These examples imply a clear requirement that cellular iron be
adequately available and properly compartmentalized for normal
physiology. However, the processes of acquisition, distribution,
and catalytic utilization of iron in the cellular environment,
which can be rich in oxygen and reducing equivalents, is not
without risk (Muhoberac and Vidal, 2013). Iron is a redox active
transition metal, which makes it substantially different from
sodium, potassium, calcium, and zinc in that it is often involved
in single electron transfers. Improperly coordinated iron in
the labile iron pool (LIP) of cells can produce reactive oxygen
species (ROS) that modify the structure of proteins, lipids, and
nucleic acids, causing an immediate local problem of loss of
normal function, but also protein aggregation through protein
destabilization and unfolding. Additionally, proteins with
mutations alone are often destabilized enhancing susceptibility
to unfolding and aggregation. Finally, iron also has the ability to
enhance aggregation of proteins that have regions of intrinsic
sequence disorder, which are generally considered as normal
functional sequences that are independent of mutation or
ROS modification, and some of these aggregation-sensitive
proteins are key players in several neurodegenerative diseases.
For example with Parkinson disease (PD), alpha-synuclein,
which has as its normal sequence a partially disordered stretch
of amino acids that take up variable structural conformations,
is especially sensitive to iron levels in that iron enhances its
aggregation (Wolozin and Golts, 2002; Theillet et al., 2016).
Similarly, the partially disordered amyloid β (Aβ) peptide in
Alzheimer disease (AD) undergoes aggregation with iron (Liu
et al., 2018). Furthermore, these aggregates have the ability to
induce iron redox changes as well as generate ROS (Hands et al.,
2011; Liu et al., 2018). Both dysregulation of iron metabolism
and iron accumulation in specific regions of the brain are directly
associated with several less common neurodegenerative diseases,
i.e., the Neurodegeneration with brain iron accumulation
(NBIA) diseases (Rouault, 2013; Meyer et al., 2015), but also
apparently with several other more commonly encountered ones
(Oshiro et al., 2011). To address the issues of availability of iron
as metabolically crucial and the potential toxicity of improperly
coordinated iron, ferritin has evolved as the end point protein to
remove and store excess iron safely and provide it to the cell as
required, and thus to reduce cellular damage and stress.
The importance of native ferritin in normal physiology, as well
as its purified availability for in vitro research, has made it one of
the more well-studied proteins over several decades (Crichton,
2009). While the mechanism of iron uptake and storage as
an iron mineral in its interior is complex but relatively well-
understood, the mechanism of iron release, although generally
considered to involve lysosomal degradation through the process
of ferritinophagy, has research suggesting alternative pathways.
These alternatives are release (1) induced by small cytosolic
molecules usually found close to ferritin or (2) by the proteasome
(Liu et al., 2003; DeDomenico et al., 2009; Tang et al., 2018).
Such pathways may be involved in general or perhaps more
nuanced iron management. More recently, mutant forms of
ferritin in which the C-terminal alpha helix is disordered and
unraveled at the four-fold pores providing an iron exit and
entry pathway that is normally considered closed, have been
characterized (Muhoberac and Vidal, 2013). These mutant forms
were discovered through clinical investigation and molecular-
level characterization of the neurological disorder hereditary
ferritinopathy (HF) or neuroferritinopathy, which has some
clinical characteristics similar to PD. Inclusion bodies (IBs)
containing ferritin, increased iron levels, and oxidative damage
(carbonylation) are found in brain samples of patients with
HF upon autopsy (Vidal et al., 2004). These characteristics are
to a great extent reproducible for investigation with cellular
and animal models expressing mutant ferritin. Such ferritin
expressed and purified from cell cultures undergoes both (1)
precipitation with increasing iron and (2) oxidative damage,
i.e., carbonylation, proteolysis, and crosslinking, in the presence
of physiological concentrations of iron and ascorbate found
in the brain (Baraibar et al., 2012). Here ascorbate functions
as a reductant so that iron can produce ROS. Dealing with
elevated iron, ROS formation, aggregation, oxidative damage, and
IB formation in HF, requires the use of cellular synthesis, transport,
repair, and disposal mechanisms and may provide a source of
cumulative cellular stress and damage as cells age.
The finding of elevated iron in HF, PD, AD, and other
neurodegenerative diseases suggests the importance of tight
physiological control of iron compartmentalization and
concentrations, and leads to consideration of ferroptosis, which
is a newly described form of rapid programmed cell death
clearly different in cellular structural changes and biochemical
pathways from apoptosis and necrosis (Dixon et al., 2012;
Stockwell et al., 2017). Characteristics of ferroptosis are lipid
peroxidation and abundant or elevated iron. Ferroptosis
may be enhanced through the process of ferritinophagy, by
which ferritin is delivered to the lysosome for degradation
and a large quantity of iron can be rapidly released enhancing
ROS production (Latunde-Dada, 2017). However, the overall
ferroptotic process is complicated in that damage can be
repaired by a particular glutathione peroxidase if sufficient
glutathione is available. Importantly, ferroptosis appears to be
strongly connected with cell death in neurodegenerative diseases
(Tang et al., 2018). In HF there are elevated iron and lipid
peroxidation similar to ferroptosis, but at least three mechanisms
of ferritinophagy inhibition may be operative, suggesting that
it is the leaky four-fold pores and modestly elevated iron that
triggers a long term cellular ferroptotic-like state gradually
and cumulatively leading to cellular misfunction and decline.
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TABLE 1 | FTL genetic variants associated with Hereditary Ferritinopathy
(neuroferritinopathy).
Mutation Amino acid change References
c.439_440 het_dupG p.Asp147GlyfsX34 Yoon et al., 2019
c.442dupC p.His148ProfsX33 Mancuso et al., 2005
c.439_442dupGACC p.His148ArgfsX34 Kubota et al., 2009
c.458dupA p.His153GlnfsX28 Devos et al., 2009
c.460dupA p.Arg154LysfsX27 Curtis et al., 2001
c.467_470dupGTGG p.Gly157GlyfsX24 Ni et al., 2016
c.468_483dup16 p.Leu162TrpfsX24 Nishida et al., 2014
c.469_484dup16 p.Leu162ArgfsX24 Ohta et al., 2008
Storti et al., 2013
c.497_498dupTC p.Phe167SerfsX26 Vidal et al., 2004
A contribution to decline is the accumulation of ferritin
aggregates from ferritin overproduction and iron binding, which
causes a variety of stressful secondary effects on synthesis,
transport, and disposal, as well as providing additional ROS
generating sites. The complicated interrelationships between the
molecular-level processes described above and HF are reviewed
herein, with the further objective that this presentation will
provide a better understanding of the common threads among
protein aggregation, elevated iron, and ROS damage found in
neurodegenerative diseases.
GENETICS, CLINICAL PRESENTATION,
AND PATHOLOGY OF HF
HF or neuroferritinopathy is inherited in an autosomal dominant
pattern. Linkage analysis established a relationship between the
disease and a locus on chromosome 19q13.3, which contains
the ferritin light chain (FTL) gene, consisting of four exons and
three introns (Curtis et al., 2001). Mutations in the FTL gene
causing HF have been reported in individuals with a Caucasian
ancestry and in East Asian populations from Japan, Korea, and
China, presenting with abnormal involuntarymovements (Curtis
et al., 2001; Vidal et al., 2004; Mancuso et al., 2005; Ohta et al.,
2008; Devos et al., 2009; Kubota et al., 2009; Storti et al., 2013;
Nishida et al., 2014; Ni et al., 2016; Yoon et al., 2019). Mutations
in FTL consist of nucleotide duplications in exon 4 that affect
the C-terminal residues of the FTL polypeptide (Table 1). There
are no known polymorphisms in the FTL gene that may affect
the clinical and pathological phenotype. In addition to the cases
indicated in Table 1, two more cases of HF have been described.
One case was diagnosed pathologically and no genetic data is
available (Schröder, 2005). The second case consists of a missense
mutation (A96T) in the FTL gene in an individual without
significant involvement of the putamen, thalamus, and substantia
nigra that did not show autosomal dominant transmission since
the mother of the proband, also a carrier of the A96T mutation,
had similar MRI findings and was asymptomatic (Maciel et al.,
2005). The A96T variant has been recently shown to be stable
under physiological conditions and incorporate iron comparable
to that of wild-type FTL ferritin (Kuwata et al., 2019).
The onset of clinical signs and symptoms may occur between
the second and seventh decade of life and depending on the
specific mutation, the disease may become evident from the
third to the fifth decade of life (Vidal and Ghetti, 2015). HF
occurs equally in males and females, with duration ranging from
a few years to several decades (Curtis et al., 2001; Vidal et al.,
2004, 2011; Mancuso et al., 2005; Ohta et al., 2008; Devos et al.,
2009; Kubota et al., 2009; Ory-Magne et al., 2009; Storti et al.,
2013; Nishida et al., 2014; Ni et al., 2016; Yoon et al., 2019).
The clinical presentation of the disease may be highly variable
not only between families but also within a family, suggesting
that a heterogeneous presentation may be a characteristic of
HF (Ory-Magne et al., 2009). The disease may present as a
movement disorder with tremor, cerebellar signs, Parkinsonism,
dystonic, and choreic movement; in addition, pyramidal and
pseudo-bulbar symptomsmay be present. Although dystonia and
dysarthria are the main manifestations of HF, the disease cannot
be diagnosed only on the basis of clinical symptoms alone. In
more advance stages, psychiatric and cognitive symptoms may
become evident (Curtis et al., 2001; Vidal et al., 2004, 2011;
Mancuso et al., 2005; Chinnery et al., 2007; Ohta et al., 2008;
Devos et al., 2009; Kubota et al., 2009; Ory-Magne et al., 2009;
Storti et al., 2013; Nishida et al., 2014; Ni et al., 2016)
Neuroimaging studies allow regional characterization of
normal vs. abnormal iron deposition through T2∗-weighted
images (WI) and susceptibility weighted imaging (SWI). These
studies show in the early clinical stage of HF the presence of
an abnormal decrease in T2∗ signal intensity reflected as hypo-
intense lesions in the basal ganglia on particularly in the globus
pallidus and putamen, which signifies abnormal accumulation of
iron (Curtis et al., 2001; Vidal et al., 2004, 2011; Mancuso et al.,
2005; Chinnery et al., 2007; McNeill et al., 2008; Ohta et al., 2008;
Devos et al., 2009; Kubota et al., 2009; Ory-Magne et al., 2009;
Ohta and Takiyama, 2012; Storti et al., 2013; Nishida et al., 2014;
Ni et al., 2016; Yoon et al., 2019). With the progression of the
disease the signal loss extends to the dentate nucleus, substantia
nigra, and cerebral cortex.
Macroscopic examination of the brain of patients with
HF reveals mild cerebral and cerebellar atrophy as well
as cavitation of the putamen. Neuropathological data is
available for individuals with the c.442dupC, c.460dupA, and
c.497_498dupTCmutations (Curtis et al., 2001; Vidal et al., 2004;
Mancuso et al., 2005). The caudate nucleus and putamen may
show a grayish discoloration. At neuropathologic examination,
the main findings are the presence of ferritin IBs in the
cytoplasm and nuclei of glial cells and some subsets of neurons,
and abnormal iron deposition in IBs, in particular in the
caudate nucleus, putamen, and globus pallidus. IBs can be
seen as eosinophilic, homogenous bodies on haemotoxylin
and eosin staining, and can be stained using the Perls’
and Turnbull blue methods for iron (Figure 1; Vidal et al.,
2004). Different from other IBs such as those containing α-
synuclein in Lewy bodies in PD and dementia with Lewy
bodies (DLB) (Spillantini and Goedert, 2018), ferritin IBs do not
show electron dense fibrillar structures on electron microscopy
(Figure 2) and cannot be stained by thioflavin S, but are
strongly immunopositive using antibodies against ubiquitin. In
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FIGURE 1 | Numerous inclusion bodies containing iron are present in the brain with a case of hereditary ferritinopathy. In HF, the most striking pathologic alteration is
the presence of intranuclear and intracytoplasmic bodies in glial cells and in some subsets of neurons. Sections of the putamen show numerous ferritin bodies of
various sizes stained by H&E (a). Iron-containing ferritin inclusion bodies stained with the Perls’ method for iron (b) and immunostained using antibodies specific for
the mutant ferritin light chain polypeptide (c). FTL immunoreactivity is seen in the nuclei and also in the cytoplasm. Perls’ staining and antibodies against wild-type and
mutant FTL subunits were used as previously described (Vidal et al., 2004). Scale bars: (a–c), 50µm.
FIGURE 2 | Electron microscopy of IBs in patients with HF. High-power electron micrograph showing ferritin accumulation in the putamen (a), in the nucleus of
granule cells of the cerebellum (b), and skin (c). Note the chromatin accumulation toward the nuclear membrane.
the cytosol, ferritin may be dispersed or forming IBs showing
a spherical appearance. Intranuclear IBs measure between 2
and 35µm in diameter, and may occupy almost completely the
nucleus and as a result displace the chromatin up against the
nuclear membrane. Antibodies against the N-terminus of FTL
as well as antibodies against ferritin heavy chain (FTH1) and
mutant-specific antibodies strongly label ferritin IBs of all sizes
in glial cells and in nerve cells (Vidal et al., 2004). The use of
antibodies also show the presence of diffuse deposits, perhaps
early aggregates, in the cytoplasm (Figure 1; Vidal et al., 2004.
Markers for lipid oxidation are also evident by immunostaining
(Mancuso et al., 2005).
In the neocortex, intranuclear and intracytoplasmic ferritin
immunopositivity is present throughout the cortical layers,
with the exception of layer I and II (Vidal and Ghetti, 2015).
Intranuclear IBs are seen in perineuronal satellite cells and in
perivascular glia. The caudate nucleus, putamen, and globus
pallidus contain the largest numbers of IBs. In these areas,
extracellular ferritin aggregates may also be found, probably as
the result from the coalescence of multiple bodies. Intranuclear
IBs may be seen in neurons of the putamen, globus pallidus, and
thalamus, and occasionally, ferritin immunopositivity may be
seen in the leptomeningeal and parenchymal vessel walls as well
as in leptomeningeal cells. In the cerebellum, IBs are seen in the
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FIGURE 3 | Ferritin inclusions in FTL-Tg mice. Histological and immunohistochemical studies of a 343-days-old FTL-Tg heterozygous mouse. (a) Ferritin inclusions
are present in all areas of the hippocampus, in particular in the granular layer of the dentate gyrus and CA4. (b) Intranuclear and intracytoplasmic ferritin deposits in the
cerebral cortex immunolabeled by antibodies against the FTL polypeptide. (c–e) Ultrastructural studies showing a ferritin inclusion body in the nucleus of a neuron of
the striatum (c). The section marked in (c) was magnified in (d,e). IBs (indicated with arrows) occupy most of the nucleoplasm. The chromatin appears to be
centrifugally displaced to varying degrees, often forming a thin layer adjacent to the nuclear membrane (nm) (e). (a,b) Immunohistochemistry using antibodies against
wild-type FTL subunits as previously described (Vidal et al., 2008). Scale bars: (a), 10µm; (b), 40µm; (c), 2µm.
nuclei of glial cells, including the Golgi epithelial cells, in granule
cells and Purkinje cells. In the latter, IBs could also be found in
the cytoplasm of the perikaryon and dendrites. Glial cells of the
white matter are affected as well. IBs are also found in the nuclei
of endothelial cells, in cells of the vascular adventitia and in the
epithelium of the choroid plexuses; ependymal cells appear to
be free of IBs. IBs have been reported in the skin, kidney, liver,
and muscle in affected individuals from French and American
families (Vidal et al., 2004; Mancuso et al., 2005). The detection
of ferritin IBs in biopsies of the skin or muscle may be helpful for
the pathologic diagnosis of symptomatic individuals (Figure 2;
Vidal et al., 2004, 2011).
Low serum ferritin levels were initially reported in individuals
with the c.460InsAmutation (Curtis et al., 2001); however, serum
ferritin levels are decreased in some but not all patients with HF
(Muhoberac and Vidal, 2013; Yoon et al., 2019). Interestingly,
CSF ferritin levels were significantly lower than normal in a
patient with the c.469_484dup16 mutation who had normal
serum ferritin values (Nishida et al., 2014). Additional studies are
needed to establish whether CSF ferritin levels could be used as a
novel biomarker for HF.
MODELING HF IN CELLS AND MICE
A mouse model of HF (FTL-Tg) that expresses the human
mutant ferritin FTL subunit p.Phe167SerfsX26 (mtFTL) has been
extensively characterized and also used to generate astrocytes
and primary mouse embryonic fibroblasts for in vitro studies
(Barbeito et al., 2009; Li et al., 2015) that complemented studies
using fibroblasts from patients with HF (Barbeito et al., 2010).
Expression of the transgene in the mouse yields a progressive
neurological phenotype, with a significant decrease in motor
performance, shorter life span, misregulation of ironmetabolism,
and evidence of oxidative damage (Vidal et al., 2008; Barbeito
et al., 2009; Deng et al., 2010). Mutant HF mice form nuclear
and cytoplasmic ferritin IBs in glia and neurons throughout the
CNS and in organ systems outside the CNS, as found in patients
with HF (Figure 3; Vidal et al., 2004, 2008). Both cytosolic
and nuclear inclusions grow larger in size and number as the
animals age to the point of crowding other cellular structures
potentially causing mechanical disruption of cellular processes
like transport. DNA oxidative damage is detected associated with
nuclear mitochondria (Deng et al., 2010) at 12 months but not 6
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FIGURE 4 | Immunohistochemistry of kidney in iron-loaded and control FTL-Tg mice. Sections of the kidney of control (a), iron treated (b), and DFP treated (c) FTL-Tg
mice immunostained using antibodies specific for the mutant ferritin light chain polypeptide as previously described (Garringer et al., 2016). Iron loaded mice appear to
have a larger number of IBs while DFP treated FTL-Tg mice showed the presence of a diffuse ferritin staining in tubule cells of the kidney. Scale bars: (a–c), 20µm.
months of age. Ferric iron accumulation is detected throughout
the CNS through Perls’ Prussian blue staining in histological
sections and T2-weighted imaging in vivo. There is evidence
of proteosomal involvement at the ferritin inclusions, including
ubiquitination and the presence of the 11S and 20S subunits.
Ferritin inclusions from the transgenic mice are SDS insoluble
as found in HF patients. The SDS insoluble IBs suggests a rather
strong association of the ferritin 24-mers (Vidal et al., 2008),
which could occur through iron bridging as might be expected
with a disordered and extended C-terminus and perhaps
including contributions from partial unfolding and proteolysis.
Additional studies show a substantial increase in cytoplasmic
ferritin (∼200–400%) depending on the subunit identity from
antibody labeling and cortex vs. cerebellum sampling (Barbeito
et al., 2009). There is a statistically significant increase in non-
heme iron levels between controls and transgenic HF mice of
∼15% (cortex) to 20% (cerebellum), but these levels are more
modest than the protein increases above. Evidence is found for
elevated oxidative protein and phospholipid damage through
detection of HNE-protein modifications, protein carbonyls, and
lipid peroxidation products like MDA in the transgenic HF mice.
Radical formation is found through immunohistochemistry of
nitrone-protein adducts. Thus, this mouse model produces only
modest increases in iron levels vs. controls, but substantial,
cumulative overproduction and lack of clearance of ferritin, as well
as oxidative damage.
Similar dysfunction is observed in primary culture skin
fibroblasts with the FTL subunit p.Phe167SerfsX26 mutation
obtained from a HF patient (Barbeito et al., 2010). The HF
fibroblasts show accumulation ofmutant ferritin in the cytoplasm
and nucleus. There is a substantial increase in ferritin content
in the HF cells of ∼320 and 470% in the FTH1 and FTL
subunit concentrations, respectively, but the increase in total iron
content is again modest at 25%. Also, a modest increase in ROS
concentration is found in the HF cells over normal, which was
further enhanced by FAC treatment.
In primary mouse embryonic fibroblasts (MEFs) from FTL-
Tg mice, there is initially a substantial increase in the levels
of soluble mtFTL, but not in the levels of insoluble mtFTL.
After incubation with ferric ammonium citrate (FAC), MEF cells
became less viable (3–5 days) and contained more iron thanMEF
cells from wild-type mice by ∼40%. Thus, the combination of
mutant-containing ferritin and iron leads to aggregation into
SDS resistant aggregates (Garringer et al., 2016). Incubation
with the iron chelator deferiprone (DFP) after iron loading
removes substantially more iron from the cells than the controls,
which suggests the iron is more loosely bound in the cells
expressing mtFTL as would be expected if the iron is initiating
aggregation and relatively loosely bound to the C-termini and
surface region of ferritin spheres rather than internally as a
mineral. In earlier studies, transgenic astrocytes were loaded with
iron by FAC incubation causing substantial conversion of ferritin
to a SDS insoluble form, but incubation with the iron chelator
phenanthroline led to a substantial reversal back to a soluble form
(Baraibar et al., 2008). Along these lines, in vitro studies using
purified mtFTL homopolymeric recombinant ferritin that was
precipitated by iron can be partially resolubilized by addition of
the chelator deferoxamine (Baraibar et al., 2008).
An interesting but perhaps counterintuitive result is obtained
in studies of FTL-Tg mice under iron loading and chelation
treatment (Garringer et al., 2016). Here, iron overload and
DFP treatment of the mouse model have remarkable effects
on systemic iron homeostasis and ferritin deposition, without
significantly affecting CNS pathology (Figure 4). The data
obtained using the FTL-Tg mouse model is in agreement
with previous observations indicating lack of effectivity of a
chelation therapy in individuals affected by HF (Chinnery et al.,
2007; Kubota et al., 2009; Storti et al., 2013). Chinnery et al.
(2007) treated three patients with monthly venesection for 6
months. Two of the patients also were treated with intravenous
deferoxamine (4,000mg weekly subcutaneously for up to 14
months), and one had oral DFP (2 g, three times a day for 2
months). These treatments cause profound and refractory iron
depletion without significant benefits for the patients. Kubota
et al. (2009) treated a patient with monthly venesections (400
mL/mo) for 2 months without any change in the clinical
condition of the patient. Storti et al. (2013) did a 6-month trial
with DFP (15 mg/kg/day) in one patient without any signs of
improvement. Work on the mouse model also suggests that
systemic ferritin deposits in HF (Vidal et al., 2004) may not
be useful to monitor therapeutic approaches since they may be
modified independently from brain ferritin deposits.
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FIGURE 5 | Ferritin 24-mer spherical shell emphasizing the disordered four-fold pore in HF. The three-fold and four-fold pores of the ferritin shell are found at the
center of the spheres (a,b). The ferritin subunits are colored differently for emphasis, and a single subunit (c) is pictured from above (outside) the shell with the short
red E-helix pointing inwards. The intact four-fold pore (d) contrasts two examples (e,f) of the many different C-terminal conformations from unraveling and disorder
revealed by X-ray crystallography of the p.Phe167SerfsX26 mutant FTL. Pictures are made from crystallographic structures in the RCSB database using files 2fg8,
2ffx, and 4v6b (mtFTL), and (d–f) are interior views.
To determine whether loss of function of the FTL subunit
in the brain could lead to some of the pathologic features
observed in HF by loss of the iron storage function of ferritin,
a Ftl knock-out (Ftl−/−) mouse model was generated (Li
et al., 2015). Interestingly, Ftl−/− mice are viable (knock-out
of the Fth subunit is embryonic lethal) and do not show signs
of neurodegeneration, presence of an inflammatory process,
noticeable protein aggregates, or iron accumulation as in patients
with HF, suggesting that the deleterious effect(s) caused by
mutant FTL subunits in HF are driven by disruption of the
ferritin pore structure and unraveling of the C-terminus in
the heteropolymer rather than by a loss of normal function of
the FTL subunit itself. Importantly, Ftl−/− mice show that Fth
ferritin homopolymers are capable of maintaining brain iron
homeostasis in vivo, paving the way for the development of a
potential therapeutic approach for HF using RNA interference
to induce sequence-specific post-transcriptional gene silencing of
mutant FTL (Li et al., 2015).
FERRITIN STRUCTURE, FUNCTION, AND
NORMAL IRON INCORPORATION
The functions of ferritin are to (1) sequester and store excess
ferrous iron, when necessary in large amounts, removing it from
the LIP and thus preventing deleterious cellular processes such
as ROS generation, protein aggregation, and iron deposition, and
(2) to allow release of this iron as needed for cellular processes.
Storage is accomplished by converting ferrous iron into a less
reactive and compact form of ferric iron oxide “mineral” that is
stored in the interior of ferritin, which has the form of a spherical
shell to contain it. Spatial storage efficiency (i.e., density of the
ironmineral) is high in that storage does not require separate iron
ions be chelated by a single protein or a small molecule chelator
in a 1:1 or 1:2 ratio.
Ferritin is a molecule assembled from 24 protein subunits
into a highly symmetric protein shell (Figures 5a,b) of exterior
diameter ∼12 nm and a hollow core of ∼8 nm that can store
up to 4,500 iron atoms within its shell (Harrison and Arosio,
1996; Crichton and Declercq, 2010). Native human ferritin is
a heteropolymer composed of FTH1 (MW∼21 kDa) and FTL
(MW∼20 kDa) subunits in varying ratios depending on the
cell/organ of origin such that its storage rate and ability is
optimized for its location. Both subunits are composed of four
parallel and closely associated alpha-helix bundles (A–D) and
a fifth alpha-helix (E) that is shorter and not aligned with the
others but rotated approximately perpendicular (∼60 degrees;
Figure 5c). The E helix points inwards from the ferritin spherical
surface and forms the sides of a pore (see below). The two
different subunits diverge in amino acid identity (∼55%), but fold
into an almost identical 3-dimensional structure, which allows
them to assemble into a highly symmetric shell with tight fitting
inter-subunit surfaces and junctions exhibiting three-fold and
four-fold symmetry (Figures 5a,b). This assembly forms eight
more polar three-fold pores of∼6 Å length and∼3.4 Å diameter
and six more apolar four-fold pores of <3 Å diameter and ∼12
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Å length, with the latter generally considered closed to iron
passage (Harrison and Arosio, 1996; Crichton and Declercq,
2010). The FTH1 subunit contains the ferroxidase center, which
oxidizes the ferrous ions in preparation for mineral formation
and the FTL subunit contains clusters of negatively charged
residues which foster the nucleation and mineral growth. The
three-fold pores are the ferrous iron entry pathways and there
is a group of negatively charged residues that help transport
the iron through the pore, along the interior of the shell to the
ferroxidase site, and then to the nucleation and mineralization
points. The specifics of the iron acquisition, transport, catalytic
oxidation, and deposition processes in ferritin, i.e., identification
of the specific metal binding amino acid residues involved in
the ferroxidation and the overall pathway from ferrous iron to
ferric mineral, have been elucidated in detail over a decade or
more of study (Masuda et al., 2010; Tosha et al., 2010; Behera
and Theil, 2014; Pozzi et al., 2015). Interestingly, homopolymeric
ferritin 24-mers composed of only FTL subunits can load iron
into the shell, but at a much reduced rate vs. heteropolymeric
ferritins, which can coordinate the iron deposition process
between subunits.
MUTANT FERRITIN STRUCTURAL AND
FUNCTIONAL ANOMALIES
Over the last decade there has been a substantial amount
of research describing the molecular level structural and
functional differences between normal ferritins and those
containing mutant FTL subunits made possible by cloning,
bacterial expression, and purification. Our studies focused on
the p.Phe167SerfsX26 mutation that causes a 9 amino acid
substitution and a 16 amino acid extension of the C-terminus out
of a total 174 amino acids (Baraibar et al., 2010). This substantial
change into a completely non-native sequence does not prevent
mtFTL subunits from assembling into homopolymeric 24-mer
spheres, with ultrastructure quite similar to the native, that
are crystallizable. This mutation encompasses part of the E
helix, but as demonstrated by X-ray crystallography in different
subunits of a 24-mer the helix unraveling can be found to
range from just before the mutation to 10 or more amino
acids toward the D helix. The unraveling distribution (i.e., the
number of amino acids disordered as to not be visible by X-
ray crystallography) is statistical over the six four-fold pores and
the four C-termini composing each of them (Figures 5d–f). The
result is a substantial disordering of what was a tight four-fold
pore into a more flexible, iron permeable structural defect and
an unraveling of the C-terminal sequence that, if extended from
the exterior of the shell, could reach as far as the entire diameter
of ferritin. This statistical disordered structure is important not
just for iron leakage, but because the disordered C-termini will
take up various orientations and conformations as potential iron
binding sites. Several amino acid residues of the disordered C-
terminus are known iron binding ligands and the disorder and
conformational sampling adds variability to their potential iron
chelation geometry in a search for free energy minimization. As
mentioned previously, redox active improperly coordinated iron
is problematic as a ROS generator causing protein (including
ferritin) modification, and the multiple C-termini conformations
may enhance the generation probability. Additionally, sampling
multiple conformations can enhance the probability of iron
bridging two C-termini either on a single mutant-containing
ferritin or between two mutant-containing ferritins enhancing
aggregation (Muhoberac and Vidal, 2013). Indeed, because
of the extremely close packing of the cytoplasm, this C-
terminal extension has the potential to interact with multiple
cellular constituents, e.g., small molecules, proteins, bilayers,
cytoskeleton component, etc., with unpredictable results.
In vitro studies show that the four-fold pore-centered FTL
mutation has several consequences. Firstly, homopolymeric
ferritin composed of mtFTL subunits is more susceptible to
iron-loading induced aggregation and precipitation than ferritin
composed of wild type FTL (wtFTL) subunits. In standard iron-
loading assays, precipitation occurs starting at approximately
an iron to mtFTL ferritin (24-mer) ratio of 1,500:1, with
homopolymers of wtFTL remaining soluble to >4,000:1 ratio
(Baraibar et al., 2008). Although the iron concentration was
high, these experiments point out fundamental differences in
the interaction with and handling of iron between mutant and
wild-type ferritins. Secondly, with heteropolymeric ferritin, this
aggregation tendency extends to the cases in which mtFTL
subunits are combined with those of either wtFTL or FTH1
to form ferritin 24-mers (Muhoberac et al., 2011). Specifically,
reduction in the percent of mtFTL subunits by half and having
the remainder provided by either wtFTL or by FTH1 causes
no aggregation at an iron to ferritin ratio of 1:1,000 (as above)
but substantial aggregation at a 3,000:1 ratio. Clearly, protection
is not provided by a large reduction in the number of mutant
subunits. Thirdly, the overall stability of homopolymeric ferritin
composed of mtFTL subunits is compromised with respect to
that of the wtFTL in temperature denaturation and proteolysis
studies (Baraibar et al., 2008). However, it is known that wtFTL
homopolymers are more stable than FTH1 homopolymers such
that the inclusion of wtFTL subunits in native heteropolymeric
ferritin is considered stabilizing. Although the loss of stability
of the homopolymeric mtFTL 24-mers is found to not be
substantial, any loss suggests the possibility of more general
enhanced local unfolding causing repositioning and exposure,
if only transiently, of normally buried or hydrogen bonded
residues. Supporting this unfolding process is the enhanced
thermolysin proteolysis of mtFTL over wtFTL homopolymers
in which a 17 kDa N-terminal fragment is produced from the
mutant but not the wild type. The position of this fragment in the
sequence strongly suggests substantial transient fluctuations in
overall mutant ferritin structure even though ultrastructurally the
mutant is spherical and crystallizable. Fourthly, susceptibility to
ROS damage of mtFTL homopolymers is enhanced substantially
over that of ferritin composed exclusively of wtFTL subunits.
At physiological concentrations of iron and ascorbate, mtFTL
homopolymers undergo substantial proteolysis (6 and 14 kDa
fragments), crosslinking (27 kDa fragment), and carbonylation
(Baraibar et al., 2012). Ferritin composed of wtFTL subunits
alone does not undergo these changes and a hydroxyl radical
scavenger prevents mtFTL homopolymer from undergoing such
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disruptive modifications implying a mutant ferritin-centered,
ROS-generating reaction initiated by iron and ascorbate. These
results strongly suggest that the mtFTL homopolymer has one
or likely more iron binding sites available that generate ROS
which attack ferritin and may attack other proteins and lipids,
as discussed in the next section.
With respect to the function of iron incorporation, defects
are found in both the mtFTL homopolymer and the 24-
mer heteropolymers. A comparison of iron uptake between
heteropolymers composed of half FTH1 and half of either
mtFTL or wtFTL subunits demonstrates a 50% reduction in iron
incorporation with a 1,000:1 ratio of iron to heteropolymeric
ferritin (Muhoberac et al., 2011). This ratio is below that
found to cause iron precipitation suggesting there exists an
iron incorporation defect caused by the four-fold structural
perturbation in HF that exists at the level of single ferritin
heteropolymers containing the mutant subunit. In addition,
small soluble aggregates not yet large enough to form precipitates
could also hinder the sequestration of iron. Taken together,
the above-mentioned in vitro studies suggest that the overall
structural and functional effects of the mutation are quite
substantial and damaging, and may require a variety of
cellular processes for correction and compensation, which are
energetically costly to the cells. It is interesting to note that in
PD there is a decrease in the concentration of FTL polypeptides
in the substantia nigra, which in a manner parallels the mtFTL
dysfunction in HF in that both lead to similar changes in LIP iron
(Koziorowski et al., 2007; Friedman et al., 2011).
IRON CHEMISTRY, INTERACTIONS, AND
REACTIVE OXYGEN SPECIES
The importance of iron to cellular function must be understood
within the context of its versatile, but complex chemical behavior
and its difficulty in cellular processing, transport, and storage
(Shriver and Atkins, 2006; Crichton and Declercq, 2010). Iron
can not only undergo redox cycling between ferrous and ferric
states, but its ability to be cycled at a particular redox potential
strongly depends on its cellular ligation, i.e., the ligands from
proteins or small molecules that are bound to it. Ferrous iron
prefers coordination to nitrogen or sulfur-containing ligands
whereas ferric iron prefers those that contain oxygen such as
aspartate and citrate. This preference is part of a chemical
classification of binding that is dependent on atomic radius
and polarizability of the atoms in contact (Shriver and Atkins,
2006). Iron coordination not only varies its redox potential, but
can determine its behavior as an electron relay or a catalytic
center, and such processes generally require some level of
conformational control of as well as outright exchange of iron
coordination by the chelating protein and substrate. Reductant
concentration and cellular packing also factor into the iron redox
state. Iron can interact with dioxygen producing potentially toxic
ROS that modify proteins and phospholipids, and this reaction
is substantially enhanced by iron with <6 coordinate ligand
shell (Graf et al., 1984). Such improperly coordinated iron is
found, even transiently, in the LIP with small cytosolic molecules
and with mutant, denatured, and aggregated proteins. Even
protein aggregation and precipitation of unmodified proteins,
especially those with regions of intrinsic sequence disorder, can
be enhanced substantially by iron presence, as is found with α-
synuclein and Aβ (Mantyh et al., 1993; Golts et al., 2002; Everett
et al., 2014; Boopathi and Kolandaivel, 2016). Indeed, there are
iron deposits and interactions with specific proteins that are
routinely found in association with neurodegenerative diseases
(Zecca et al., 2004; Carboni and Lingor, 2015; Ward et al., 2015;
van Bergen et al., 2016; Liu et al., 2018). Aqueous iron solubility
itself varies substantially between its ferrous and ferric forms,
with the ferric form basically insoluble near neutral pH and
requiring cellular carriers such as small molecule chelators or
proteins, but with ferrous iron soluble near 100mM (Crichton
and Declercq, 2010). Because of this level of molecular behavioral
complexity and the number of cellular constituents with which
iron can interact, the cell has developed a variety of mechanisms
to employ iron in biochemical catalytic processes as well as to
deal with excess iron and iron-produced ROS, which potentially
negatively effects proteins, lipids, and DNA.
The most common cellular ROS—hydrogen peroxide,
superoxide, and the hydroxyl radical—vary substantially in
their origin, interactions, lifetime, and toxicity (Halliwell
and Gutteridge, 2007; Auten and Davis, 2009; El-Beltagi
and Mohamed, 2013; Davies, 2016). The hydroxyl radical is
considered the most toxic with a high reactivity and short
diffusion distance, causing protein backbone cleavage, oxidative
residue modification, crosslinking, nucleic acid modification,
and lipid peroxidation close to its sight of generation, although
once initiated the peroxidation damage can spread. Hydrogen
peroxide is not particularly reactive with a large ability to
diffuse and is part of a redox signaling mechanism in cells,
and superoxide is considered of intermediate toxicity. There
are enzymes that normally produce these ROS for biochemical
and defensive purposes, and ROS may also originate with
damaged enzymes or those that on occasion miscycle during
normal catalysis (Turrens, 2003). The characterization of
ROS availability is further complicated by the potential
interconvertability of these species both by detoxifying enzymes
and local concentrations of poorly coordinated iron in the LIP.
Hydroxyl radical formation is generally discussed with respect
to two widely accepted and employed chemical generating
systems of different composition (Cohen et al., 1981; Uchida
et al., 1989; Ito et al., 1993). The first consisting of hydrogen
peroxide and a ferrous salt is the Fenton/Haber-Weiss-type
reaction which produces hydroxyl radicals (·OH) as follows:
Fe2+ + H2O2 → Fe
3+
+ ·OH + OH−
The ferrous ion is regenerated by a reaction between a ferric
iron and hydrogen peroxide or perhaps superoxide (·O−2 ) which
is formed from ferrous iron and dioxygen, and then the cycle
repeats. The second generating system consists of ascorbic
acid, EDTA, and ferric iron and is called the Udenfriend-
type reaction. This system appears to be more similar to what
might occur in vivo in that it has a supply of physiological
reductant and the iron is chelated by ligands other than water,
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hydroxide, and/or oxygen. Ascorbic acid reduces the iron, which
reacts with dioxygen to produce superoxide. Then superoxide
produces hydrogen peroxide which feeds a Fenton/Haber-Weiss-
type reaction producing the hydroxyl radical. Ascorbic acid cycles
the iron back to the reduced state producing additional hydroxyl
radicals. As might be expected, the ability of the Udenfriend-
type reaction to generate ROS is strongly dependent on the type
of iron chelation in that EDTA-iron must transiently become 5-
coordinate opening a ROS generating site. Radical generation
and the ability to modify target molecules is strongly modulated
by the choice of iron chelators that are substituted for EDTA
(Burkitt and Gilbert, 1990).
There are a number of cellular enzymatic processes to
(1) eliminate the specific ROS, converting them to water or
other ROS that are, under normal conditions in which iron
levels are controlled, less damaging, or (2) repair cellular
damage caused by them (Halliwell and Gutteridge, 2007; Kim
et al., 2015). Superoxide is catalyzed to hydrogen peroxide by
superoxide dismutase, thus exchanging one ROS for another,
which can generate a potentially more toxic species through the
non-enzymatic Fenton/Haber Weiss-type reactions. Hydrogen
peroxide can be catalyzed to water by catalase, removing it
from the toxicity cycle. Glutathione peroxidases can also convert
hydrogen peroxide to water, but doing so requires reduced
glutathione, which brings into focus the need for maintaining
the reducing potential in the brain where normal levels of
ascorbate and reduced glutathione (GSH) are relatively high (1–
2mM) (Baraibar et al., 2012). However, high levels of reducing
agents in the brain may be problematic with respect to ROS
generation. Taken together, ROS management and damage repair
are highly complex and interrelated processes that would likely
become problematic as iron levels exceeded the norm. In addition,
protein conformational changes and aggregation that result in
iron binding sites have the potential to further contribute to ROS
generation, as will be discussed later.
PROTEIN AND LIPID MODIFICATION AND
DEGRADATION BY ROS
The general characteristics of biological exposure to ROS are
deleterious oxidative modifications of proteins, lipids, and
DNA (Halliwell and Gutteridge, 2007; Suzuki et al., 2010; Yin
et al., 2011; El-Beltagi and Mohamed, 2013; Davies, 2016).
As with iron, the levels of oxidized cellular proteins and
lipids increase with age and are found in HF and other
neurodegenerative diseases. Additionally, modified proteins and
their aggregates are associated with compromised proteasomal
function inhibiting damaged protein clearance (Grune et al.,
2001; Stadtman, 2004; Hipkiss, 2006; Radak et al., 2011). Thus,
this lack of clearance and increased concentration not only
leads to enhanced protein aggregation in a cyclical manner, but
strains cellular repair and elimination processes to the point of
accumulation, diverting cellular resources from other tasks (e.g.,
biomembrane maintenance). Although ROS-centered cellular
damage is often characterized by protein carbonyl derivative
formation (carbonylation), the kinds of modifications that are
caused by ROS are much more varied (Halliwell and Gutteridge,
2007). Protein side chains can undergo substantial modification
by the hydroxyl radical depending on their identity. For example,
lysine and arginine can acquire a carbonyl, methionine can be
oxidized, phenylalanine, and tyrosine can each acquire an added
hydroxyl group, and histidine becomes 2-oxo-histidine. Such
modifications change residue physical attributes, e.g., charge
and size, and also chemical reactivity, which in turn can alter
their interactions with substrates or other proteins, decrease
protein stability, and enhance aggregation without direct iron
binding or bridging. Protein modification and unfolding has
the potential to enhance iron binding and iron binding-induced
aggregation. Loss of protein stability (partial unfolding) and the
aggregation process itself can produce new iron binding sites that
can form centers of ROS generation. Potentially more extensive
protein damage can occur because the hydroxyl radical can
also cause polypeptide backbone cleavage and crosslinking,
with the latter particularly problematic for protein repair and
disposal pathways.
Not only proteins, but lipids are subject to modification by
ROS (Yin et al., 2011; El-Beltagi and Mohamed, 2013), with
those containing more than one double bond being particularly
susceptible to radical attack and the resulting substantial
structural damage (Wagner et al., 1994). Lipid peroxidation has
been linked to a large number of diseased states including AD
and PD as well as being found with HF (Yin et al., 2011).
Such damage can clearly alter biomembrane structure, e.g.,
fluidity and phospholipid raft formation, and function, including
that of passive transport and membrane bound enzymes and
receptors. Even phospholipid-based signaling can be affected.
However, the extent of potential cellular disruption and damage is
magnified by the more complicated cyclical propagation behavior
of ROS-modified lipids that attack unaltered lipids and the several
kinds of reactive phospholipid byproducts that are formed, e.g.,
malondialdehyde (MDA) and 4-hydroxynonenal (HNE) that cause
additional damage (Halliwell and Gutteridge, 2007). There are
three steps involved in radical-centered damage to membranes:
initiation, propagation, and termination, with various sub-
reactions including direct iron involvement (Wagner et al.,
1994; El-Beltagi and Mohamed, 2013). Lipid peroxidation most
likely begins with an initiation step in which a hydrogen atom
is extracted by a hydroxyl radical from a carbon adjacent
to double bonded carbons in a polyunsaturated hydrocarbon
chain (LH to L·). The ability energetically to produce this
carbon-centered radical depends on its location relative to vinyl
groups. The hydrogen of a carbon sandwiched between two
vinyl groups, i.e., a bis allyic carbon, is most easily abstracted
followed by a carbon adjacent to a single vinyl group, i.e.,
an allylic carbon. The most difficulty hydrogen to abstract
is an acyl chain carbon away from double bonds explaining
the susceptibility of polyunsaturated lipids to radical attack.
In the propagation steps, dioxygen reacts with the carbon-
centered radical on the acyl chain (L·) forming a peroxyl radical
(LOO·), which has the ability to extract another hydrogen
from a second unmodified polyunsaturated hydrocarbon chain
producing additional damage through a second carbon-centered
radical (L·) and a lipid hydroperoxide (LOOH). This reaction
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is cyclical in propagating damage. The lipid hydroperoxide is
relatively stable but can react with iron forming hydroxyl and
alkoxyl radicals (LO·), of which both can abstract hydrogen.
Iron involvement highlights increased iron levels and improperly
coordinated iron in neurodegenerative diseases. Termination
involves the formation of more stable or non-radical products
(e.g., crosslinked LL), trapping by small molecule radical
scavengers, or enzymatic repair. However, it should be noted
that lipid hydroperoxide breakdown into reactive byproducts
such as MDA and HNE, which are well-known markers for
ROS damage and cause additional lipid and protein damage.
For example, both MDA and HNE can cause numerous types
of protein modifications, e.g., crosslinking between two proteins
and modification of the structure of residues, thus hindering
protein function and fostering aggregation. Taken together, iron
can both initiate lipid and protein damage by hydroxyl radical
formation, as well as enhance the rate of damage in a cyclical
manner, especially with lipids. These two reactive byproducts are
proximal markers for cell death involving uncontrollable lipid
peroxidation through ferroptosis, as will be discussed shortly.
FERRITIN IRON RELEASE BY
FERRITINOPHAGY AND OTHER
MECHANISMS
Under circumstances in which cellular iron is lacking, iron stored
in native ferritin can be released for cytosolic distribution, and
there are different potential mechanisms of various complexity
and divergent pathways that may do so. Such mechanisms are
lysosomal and proteasomal ferritin degradation, and removal
of iron through the ferritin three-fold pores, which have
clearly been established as the entrance channels for iron but
not as exit pathways. Current focus as the most likely and
dominant iron release mechanism in normal cells is lysosomal
degradation of ferritin through an autophagic process called
ferritinophagy (Biasiotto et al., 2015; Ndayisaba et al., 2019),
which is complicated and requires substantial cellular machinery,
i.e., transport, synthesis and degradation. However, there is
an extensive literature on completely different mechanisms
(Crichton, 2009; DeDomenico et al., 2009; Bou-Abdallah et al.,
2018), and it is not unreasonable to suggest that a fine tuned
cell would have more than one way to remove iron from ferritin
under different conditions, especially one that minimizes use
of cellular material and energy and is not spatially dispersed.
Degradation of ferritin by ferritinophagy is a complex and
spatially non-local process requiring significant cellular resources
of synthesis and transport, and even proteosomal degradation
is energetically costly and requires ATP both for labeling the
target proteins with ubiquitin and the degradation process
itself. Perhaps cells have also developed a more measured, fine-
tuned, iron release pathway utilizing locally available cellular
components such as cytosolic reductants and small molecule
chelators, and such pathways have undergone substantial in
vitro investigation (Melman et al., 2013; Koochana et al., 2018).
Thus, there may be two (or more) mechanistic levels of stored
iron release from native ferritin operating concurrently in the
cell, one for nuanced, local iron balance and the other used
under different circumstances, e.g., under iron-depleted cellular
distress. In fact, given the importance of iron management,
evolutionary sampling, and the complexity of cellular response
to environmental change, it is not unexpected that there would
be multiple mechanisms to inhibit and augment iron release
from ferritin, which is an ancient protein. Below is discussed
ferritinophagy in the context of an autophagic process as well as
the alternate more local mechanisms of iron release.
Of the two major protein degradation pathways, ubiquitin-
proteasomal and lysosomal degradation, ferritinophagy depends
upon the latter through a multistep pathway involving
autophagosomes and the cargo protein Nuclear Receptor
Coactivator 4 (NCOA4) (Mancias et al., 2014, 2015; Bellelli et al.,
2016; Gatica et al., 2018). In this pathway, NCOA4 binds ferritin
and is necessary for ferritin to be transported to lysosomes.
First, ferritin binds to NCOA4 forming a complex through an
FTH1 subunit. Next, the double walled proto-autophagosome
membrane encompasses the ferritin NCOA4 complex forming
a completely enclosed structure. Finally, the autophagosome
fuses with the lysosome in which ferritin is degraded releasing
iron. This pathway requires microtubules for transport and
assembly (Hasan et al., 2006). Further details of the NCOA4-
ferritin interaction are from (1) binding studies of a cloned and
expressed portion of the NCOA4 protein (residues 383–522)
and (2) its different interactions with FTH1, wtFTL, and single
amino acid mutations of the FTH1 subunit (Gryzik et al., 2017).
The FTH1 ferritin 24-mer can bind up to 24 NCOA4 proteins.
Furthermore, FTH1 binds to the NCOA4 fragment tightly (in
the nM range), but NCOA4 does not bind to wtFTL or to FTH1
after certain mutations. This binding specificity may be crucial
to the explanation of the accumulation of ferritin into IBs, as will
be discussed below.
HF is characterized by formation of IBs that are composed
of mtFTL, wtFTL, and FTH1 subunits, and there is clear
biochemical and histologic evidence of the accumulation of
all three types of ferritin subunits in patients with HF and
in the mouse model (Vidal et al., 2004, 2008). However, the
ferritinophagy process is based on recognition of FTH1 in
the ferritin 24-mer for lysosomal degradation and clearance,
and structurally complete 24-mers can be formed from any
combination of these subunits. Brain ferritin has FTH1 as the
predominant subunit of its normal ferritin 24-mer assembly, and
it is possible that imbalance in the ratio of mtFTL and/or wtFTL
to FTH1 subunits caused by HF, i.e., a decrease in normal ferritin
FTH1 subunit content in the 24-mer, could substantially and
negatively affect NCOA4 binding to ferritin and its clearance by
ferritinophagy. This could explain, at least in part, the buildup
of IBs in HF. More likely, inhibition of NCOA4 binding to
ferritin could be caused by just the presence of the mtFTL
in the 24-mer because of interference from the extended C-
terminus or by formation of ferritin aggregates by iron bridging.
Thus, the buildup of cellular ferritin in the form of IBs is
consistent with direct mutant-based inhibition of ferritinophagy
through compromised NCOA4-FTH1 subunit binding. Inhibited
ferritinophagy is particularly problematic in HF in that the
elevated iron from four-fold pore misfunction is a driver to
overproduction of both normal and mutant ferritin without
appropriate clearance. This feedback process would likely tax
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cellular resources and eventually cause ferritin accumulation with
multiple unwanted cellular interactions, e.g., association with
susceptible proteins, inhibition of microtubule-based cellular
transport, and altered spatial packing in a cumulative manner.
In addition, mutant-containing ferritin, together with cellular
reductants and iron would generate ROS. With ferritinophagy
compromised and ferritin accumulation the cell would likely
resort to proteasomal degradation of ferritin and the aggregates,
and there is evidence of proteasomal constituents in IBs (Vidal
et al., 2008). However, the proteasome is ill-equipped to handle
ferritin because of its size vs. the dimensions of the proteasome
interior. Ferritin 24-mers might dissociate intomonomers, which
are substantially smaller, however both normal and mutant-
containing ferritin are particularly stable. Further complicating
disposal is that protein aggregates inhibit the proteasome.
Partitioning of the proteasome into the vicinity of the ferritin
aggregates may be a failed attempt to remove ferritin or it
may be in response to ROS damage of other proteins caused
by ferritin-iron aggregates. Taken together ferritin overexpression
and compromised ferritinophagy are major components of HF, and
mutant-induced inhibition of binding of ferritin to NCOA4 may
contribute directly to small aggregate and IB formation.
Other proposed mechanisms of inhibition of ferritinophagy
are dependent on elevated iron. More specifically, in the absence
of HF, high iron levels (1) enhance proteosomal degradation of
NCOA4 and (2) inhibit the binding between FTH1 subunit and
NCOA4 (Mancias et al., 2015; Gryzik et al., 2017). However,
the modest elevation of iron in HF suggests that neither process
may dominantly inhibit ferritinophagy, and the mutation-based
direct inhibition of may contribute in parallel with, or perhaps
even dominate, the other two mechanisms. In addition, the
mechanism by which ferritinophagy is decreased by iron-induced
enhancement of proteosomal degradation of NCOA4 may not
be operative in HF with the proteasome compromised by
ferritin aggregates and unable to remove NCOA4. In any case,
there may be as many as three mechanisms working to inhibit
ferritinophagy at some stage of the progression of HF consistent
with the gradual buildup of IBs.
Several alternative native ferritin iron release mechanisms
that do not require complex cellular responses, but are instead
more direct pathways centered on ferritin interaction with locally
available cytosolic effector molecules, have been proposed from
in vitro studies (Boyer et al., 1988; Crichton, 2009; Melman et al.,
2013; Badu-Boateng et al., 2017; Johnson et al., 2017; Koochana
et al., 2018). Most of the latter do however require (1) reduction
of the iron mineral stored in the interior of the ferritin, (2) an
iron chelator, and (3) a pathway through which the chelator
and iron-chelator complex can pass through the shell. Cytosolic
molecular reductants, e.g., NADPH and FADH, and chelators are
relatively large bringing into question their ability to pass through
the three-fold pores and gain access to the ferric iron mineral,
as well as the rates in which these processes could occur. By X-
ray crystallography the pores are smaller than the dimensions
of these cytosolic effector molecules. Even if the reductant does
not need to enter the ferritin interior because electrons could
transit the shell by a redox relay mechanism, the standard three-
fold pore configuration is not designed for chelated ferrous iron
to have egress. Still, there have been reports of slow release of
iron from the ferritin interior by treatment with combinations
of reductants and chelators, and there is evidence that the
crystallographic, nominal three-fold pore diameter of ∼3.4 Å
relaxes to accommodate somewhat larger diameter molecules
(Yang and Nagayama, 1995). In any event, such iron release
would likely be slow compared with lysosomal iron release. In
HF, limitations in reductant and chelator entry and exit are
substantially reduced with the disordered four-fold pore.
Another iron release mechanism involves perturbing ferritin
three-fold pore structure directly. Such studies were performed
through amino acid mutations at the pore, binding of peptides
to the surface of ferritin, and exposure to low levels of structural
perturbants with human FTH1 24-mer ferritin and a frog FTH1
analog (Takagi et al., 1998; Jin et al., 2001; Liu et al., 2003, 2007;
Hasan et al., 2008). Site-directed mutagenesis of specific amino
acids e.g., FTH1 L138P, allows substantial modulation of the iron
egress rate by increasing pore size and/or disorder. Furthermore,
small peptides that bind to the surface of ferritin, which were
found through screening assays, and even low concentrations of
physiological perturbants modulate the iron exit rate of native
frog ferritin. Thus, it is plausible that one or more pathways
alternate to ferritinophagy may be operative in the overall
process of cellular iron balance, although available reducing
ability is necessary to dissolve the mineral core in all cases. These
processes have the potential for more nuanced control of iron
levels, perhaps with more rapid response and energetic efficiency
than ferritinophagy. However, deconvoluting these competitive
processes in a cellular environment without one masking another
and the often use of excesses of perturbants, reductants, and
chelators further complicates the already complicated scheme of
iron balance.
CELLULAR STRESS AND DESTRUCTION
THROUGH FERROPTOSIS
Ferroptosis is becoming increasingly characterized as a major
player in several neurodegenerative diseases (including AD and
PD) as well as being understood to be a new form of Programmed
Cell Death differing biochemically and morphologically from
apoptosis, classical autophagy, and necrosis (Biasiotto et al., 2015;
Gao et al., 2016; Angeli et al., 2017; Stockwell et al., 2017).
Furthermore, close sequential biochemical linkage between the
end point of ferritinophagy (iron release) and the ROS damage
in ferroptosis suggests that ferritinophagy iron release is a
component of, or perhaps an outright driver of, ferroptosis under
certain conditions (Santana-Codina and Mancias, 2018; Sui
et al., 2018, 2019). Interestingly, components of the ferroptotic
process have been reported in the literature as isolated effects
for some time now, but their connections into an overall picture
were lacking. This was in part because cellular studies from
diverse cell types found at different times that iron chelators,
antioxidants (radical scavengers), and lipoxygenase inhibitors
can cause inhibition of ferroptotic cell death (Cao and Dixon,
2016; Stockwell et al., 2017). Conversly, a different set of drugs
and small molecules were found to induce ferroptosis. Thus,
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it has been argued that ferroptosis is not really new and
there is a suggested timeline to the evolution of its etiology
(Hirschhorn and Stockwell, 2019). The two major cellular
components characterizing ferroptosis are (1) iron presence or
elevation and (2) accumulated lipid damage with inhibition of the
lipid repair process. The pathways of several contributors to the
overall ferroptotic process can be deconvoluted experimentally
and recognized individually using small molecule ferroptosis
inducers and inhibitors specific to each contributor (Cao and
Dixon, 2016; Stockwell et al., 2017), although not all have been
applied to cells involved in neurodegeneration. These studies are
complicated in that ferroptosis is often induced by one small
molecule and inhibited by another.
Paralleling HF, a picture of the crucial importance of iron
availability or excess in ferroptosis is clear, and under some
circumstances its excess may induce ferroptosis (Fang et al.,
2018; Dixon and Stockwell, 2019). Rapid ferroptosis-induced
cell death can be inhibited by preventing normal activity of
the NCOA4 cargo protein and its ability to bring ferritin to
the lysosomes for degradation through ferritinophagy, which
releases toxic levels of iron into the LIP (Mancias et al.,
2014; Gao et al., 2016). Iron chelators are able to circumvent
ferroptosis initiated by several different small molecule inducers
that work through different cellular pathways, but contribute
to the overall ferroptotic process (Cao and Dixon, 2016).
Furthermore, changing expression of ferroportin and transferrin
receptor levels, i.e., exporters and importers of cellular iron,
modulate ferroptosis as expected (Gao et al., 2016; Geng et al.,
2018; Dixon and Stockwell, 2019). Recently, it was demonstrated
that intracellular iron overload caused by treatment with a
membrane permeable iron chelation can cause ferroptosis
and cell death (Fang et al., 2018). Such studies implicate, in
addition to the need for iron availability, that an increase in
iron level itself may be a mechanism of ferroptosis initiation,
especially in stressed cells where other compensating processes
are depressed.
Lipid peroxidation is a defining process of ferroptosis leading
to cell death, and there are two major pathways which can
cause this: (1) ROS generated at improperly coordinated iron
non-specifically attacking surrounding lipids and proteins, as
well as iron enhancing the rate of lipid autooxidation, and
(2) an iron-containing lipoxygenase (LOX) which detrimentally
modifies phospholipids in a more specific (enzymatic) manner
and requires dioxygen but not reducing equivalents. Both
pathways likely occur to some extent in the ferroptotic process
and the dominant one would depend on the amount of LIP
iron accumulation without safe storage vs. LOX availability and
expression. Recently, it was found that LOX inhibitors may more
effectively function as radical scavengers than inhibitors (Shah
et al., 2018), thus adding weight to improperly coordinated iron
and ROS as a drivers of ferroptosis. Importantly, the process of
ferroptosis-induced cell death is inhibited by phospholipid repair
by a specific glutathione peroxidase (GPX4), but requires GSH
to do so, and it is known that direct covalent inhibition of GPX4
prevents repair of damaged phospholipids enhancing ferroptosis
(Yang and Stockwell, 2016). Restriction of GSH availability by
inhibition of GSH synthesis or prevention of import of its
precursor cystine also enhances ferroptosis.
In HF, the situation is more complicated in that (1)
sequestration of iron into ferritin is already compromised to
some extent with the leaky four-fold pores causing chronically
elevated iron, which enhances ROS damage without the need
for ferritinophagy releasing iron, and (2) the true extent of
ferritinophagy inhibition in HF is unclear but may be substantial
because there is significant but gradual ferritin IB accumulation.
Moderately elevated iron level and oxidative damage in HF
are suggestive of a gradual form of ferroptotic-like cell death,
which is consistent with the relatively long life span of patients
and animal models. Ongoing stress from unproductive and
compensating cellular processes would likely be an important
component. Protein aggregate formation from ferritin or other
proteins may cause other forms of cumulative damage indirectly
contributing to cell death on a time scale differing from
ferroptosis, which is rapid. Further complicating the issue is that
normal brain iron concentration increases with age (Weinreb
et al., 2012) paralleling the likelihood of onset of several different
neurodegenerative diseases, as is found with HF, and most of
these diseases are suggested to have a mechanism-based iron
component to their etiology.
THE ROLE OF FERROPTOSIS IN
HF—SIMILARITIES AND DIFFERENCES
Drawing a complete analogy between cell death from a long-term
process like HF and a short term, small molecule-induced death
process like ferroptosis is difficult in that the short term process
would not necessarily exist long enough to allow production of
long term, cumulative cellular damage. Both processes critically
involve iron, and they have ROS and phospholipid damage as
components. In HF ferritinophagy is likely eliminated or greatly
reduced, with iron levels gradually increasing from four-fold
pore leakage, which does not occur in ferroptosis. Although the
time scales differ, both HF and ferroptosis appear to respond
to increasing levels of iron in an increasingly negative manner.
Because HF has an overproduction of ferritin and a C-terminus
that allows for iron bridging, aggregates and IBs form over the
long term. This process apparently does not occur in ferroptosis,
but it would be interesting to examine what would occur if
ferroptosis could be slowed into a more long-term process and
the results compared to other forms of cellular dysfunction
in neurodegenerative diseases. Perhaps protein aggregates from
ROS damaged proteins and iron would occur in an extended
form of ferroptosis more closely paralleling neurodegenerative
diseases. In addition, GSH levels fall with age, in ferroptosis, and
in neurodegenerative diseases (Emir et al., 2010), again pointing
toward a parallel with a more long term ferroptotic-like state.
Thus, the designation of long term ferroptotic-like state in HF is
meant to capture the dependence on iron, ROS, lipid and protein
damage, and stress, and perhaps declining GSH levels in both
processes, but not to draw a complete molecular level parallel.
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Interestingly, this discussion brings up the question of time scales
in contributions to neurodegenerative diseases.
CONCLUSION
Not long ago, one could attend a seminar on major
neurodegenerative diseases and hear no or only passing
mention of transition metal ions. The same absence is still true
of some current textbooks. These lectures and texts generally
focused on aggregation and fibrillization alone. However, the
current literature is becoming increasingly clear concerning
the very important connections between iron and AD, PD,
Prion disease, motor neurone disease, and other chronic
slowly-progressing neurodegenerative diseases (Biasiotto et al.,
2015; Ndayisaba et al., 2019; Weiland et al., 2019). This review
emphasizes the complexity of the cellular problem at hand with
respect to interactions of iron with certain proteins and small
molecules as caused by HF. The inability of ferritin containing
the mutant subunit to properly store iron and its modified and
extended C-terminus have several consequences. These are
seen as measured observables in elevated iron concentration,
overproduction of ferritin, enhanced protein and lipid oxidation,
ROS generation, and aggregation and deposition of ferritin into
IBs. The elevated iron level in HF is causal to both production
of ROS and ferritin overproduction to attempt to compensate
for iron elevation. The mutant C-terminus and iron together
foster ferritin aggregation leading to IBs. However, these cellular
changes are not static endpoints and they themselves have far
reaching cellular involvements and consequences.
ROS are generated (1) by reductants and oxygen at iron
improperly coordinated by small molecules, mutant ferritin, and
ferritin or other proteins that are unfolded or aggregated, (2)
secondarily as protein and phospholipid reaction products from
primary ROS attack, and (3) from enzymes that miscycle or for
defensive purposes. Additionally, improperly coordinated iron
may cause interconversions between various ROS, and these may
increase toxicity. Once damaged by ROS, proteins tend to unfold
exposing their hydrophobic interiors that associate and form
aggregates independent of, but also potentially driven further
by, iron binding. Additionally, this process may be cyclical
because ROS can be generated from iron on aggregates and
ROS attack and damage helps aggregate proteins. Cells must
expand resource outlays and shift resources away from other
tasks to attempt to correct for ROS overproduction, protein and
lipid damage, and disposal of aggregates, which are common
stressors in neurodegenerative diseases. These cellular outlays
can take the form of additional synthesis of proteins to attempt
to restore iron homeostasis, destroy ROS, repair proteins and
phospholipids, and eliminate and transport protein aggregates,
and also to maintain redox balance and energy availability for
these as well as other normal cellular processes. These many
processes are materially and energetically costly and stress the
cell. Elevated iron and lipid peroxidation products as are found
in HF are markers for ferroptosis, which may be occurring at a
moderate level as the cells try to cope with the above-mentioned
multiple stressors.
In HF, excess ferritin synthesis, in an attempt to control
iron levels, diverts ribosomal proteins and energy away from
other necessary cellular synthesis. Ferritin disposal is also a
complex, interdependent and a somewhat redundant system
perhaps involving both the proteasome and the lysosome,
which require synthesis and energy. However, the extent and
distribution between these becomes unclear in HF especially with
respect to soluble ferritin vs. ferritin aggregates. Elements of
the proteasomal machinery are evident in IBs in HF, however
such is not likely to effectively clear excess ferritin because
of the large size of the 24-mers and aggregates making the
lysosomal clearance primary. NCOA4 binding to ferritin is
required for ferritin to be transported to the lysosome and
undergo ferritinophagy, but inclusion of the mtFTL subunit
itself, or the resulting aggregation it induces, could hinder
the binding of NCOA4 to ferritin for disposal thus enhancing
accumulation into IBs. Under the circumstance that ferritin
aggregates are not disposed of by ferritiophagy, the proteasome
likely attempts compensation. However, the formation of IBs in
HF suggests that the process of IB formation outpaces the ability
of both proteasomal and lysosomal degradation, and proteasomal
proteins may be synthesized but not effectively used for ferritin
clearance. These several cellular processes meant to compensate
or correct for the presence of mtFTL are all energetically and
materially costly, and stress the cell.
This review makes clear the complex interrelationships in HF
as the cells are stressed and muster their efforts at maintaining
overall homeostasis. The two key pathogenic mechanisms for
the phenotypic expression of the disease are best explained
(1) as a loss of normal ferritin function with decreased iron
incorporation that triggers intracellular iron accumulation and
overproduction of ferritin polypeptides, and (2) a gain of toxic
function through ROS production, ferritin aggregation, and
oxidized protein and lipid formation (Muhoberac and Vidal,
2013; Vidal and Ghetti, 2015). However, this phenotype does
not fully emphasize the layered cellular damage signified by
oxidation and aggregate formation, which may have parallels
in a number neurodegenerative diseases and lead to a major
loss of normal cellular function. The responses to (1) and (2)
above tax cells energetically, and with respect tomaterial resource
availability and management, causing gradual, but cumulative
damage. Even proteasomal action is inhibited by aggregated
proteins. Interestingly, it is found that there is only a modest
increase in iron levels (10–20%) in cells and animal models vs.
the rather large associated increase in ferritin (200–400%) found
with them. Moderate iron level increases make sense in that a
substantial increase would likely bemore rapidly lethal to the cells
through ROS production and aggregate formation, and could
shut down ferritinophagy completely if any portion was still
functional. Both humans with HF and animal models do exhibit
moderate life spans and gradually, not rapidly form IBs. Still,
because iron is redox active even low concentrations can cause
ROS damage, especially if the cellular stress is long term and to
some extent cumulative.
The presence of IBs is a diagnostic marker for HF, and they
are increased much more than the iron level. The chronic-
progressive increase of IB (number and size) through the
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FIGURE 6 | Detailed interrelationships in HF between iron accumulation, ferritin overexpression, ROS generation, other stressors, and a ferroptotic-like cellular state.
(a) The mutant ferritin subunit (leftmost box) is incorporated into ferritin 24-mers, which form spherical shells with altered four-fold pores and are functionally defective.
Mutant-containing ferritin does not incorporate iron appropriately causing increased LIP iron concentration and a feedback loop leading to ferritin overexpression to try
to control iron levels. Increasing iron causes ROS formation through multiple paths (see b) and cellular damage, as well as enhanced aggregation of mutant-containing
ferritin through bridging unraveled C-termini and from ROS damage. There are at least three mechanisms that can inhibit ferritinophagy involving NCOA4 (three vertical
(Continued)
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FIGURE 6 | circles), two caused by increased iron levels and the third by the C-terminal mutation, in addition to ferritin aggregates directly inhibiting microtubule
transport and proteosomal degradation, leading to buildup of ferritin aggregates and IBs. The combination of accumulation of ferritin aggregates and ROS damage
causes cellar dishomeostasis leading to several forms of cellular stress (rightmost box). (b) ROS can originate with cellular iron that is improperly coordinated (see
box), as well as by enzymes that misfire or form them normally. ROS can be converted to other ROS forms, sometimes more toxic, by improperly coordinated iron or
native enzymes. Certain enzymes have the function to eliminate ROS as cellular protectors. Both lipid and protein damage occur from ROS leading to local cellular
loss of function, and protein damage can lead to aggregation further enhancing and spreading ROS production. (c) Mutant-containing ferritin clearly leads to
increased iron levels, which in turn causes ROS-induced protein and lipid damage in HF. However, compensating for the long-term dishomeostasis (see box in a)
caused by mutant ferritin stresses the cell, diverting resources and energy away from bulk metabolism and taxing cellular transport and repair mechanisms, which
contributes to a long-term cellular weakening process. Increased iron and lipid peroxidation, which are both found in HF, are hallmarks of ferroptosis, which leads to
cell death and is associated with several neurodegenerative diseases. The causative factors in cell death in HF appear to be not only iron accumulation and ferritin
aggregate formation, but additionally, a combination of several gradual but cumulative forms of overall stress (a, rightmost box) causing cellular compensatory
breakdown that taken together cause a long-term ferroptotic-like cellular state.
duration of the disease points toward a serious failure of the
systems attempting to manage cellular ferritin disposition, i.e.,
lysosomal degradation through ferritinophagy. NCOA4-FTH1
binding is inhibited by high iron concentration in purified
protein studies and NCOA4 degradation is enhanced (Mancias
et al., 2015; Gryzik et al., 2017), however these may not
be enough to substantially suppress ferritinophagy. Thus, the
modest iron increases found in in vivo studies of HF do not rule
out an additional, perhaps dominant contribution to hindered
NCOA4-ferritin binding and decreased ferritinophagy that is
mechanistically separate from the two above-mentioned iron
level effects. Importantly, it is likely that the presence of the
partially unfolded mtFTL subunit in ferritin would decrease
NCOA4-ferritin binding directly through hindering the NCOA4-
FTH1 interaction and also through enhanced ferritin aggregation
making NCOA4-FTH1 interaction spatially difficult to achieve.
Additionally, aggregates of ferritin would be difficult to transport
to the lysosome or aggresomes. This may provide a mechanism
for the gradual buildup of aggregates into dispersed IBs that is
not dependent on high iron levels.
Even recently, the contribution of iron-induced aggregation
has been suggested to be unimportant in the etiology of HF
(Luscieti et al., 2010; Levi and Rovida, 2015). Such aggregation
can occur through C-terminal bridging of ferritin containing
the mtFTL subunit or by ROS oxidation and proteolysis of
ferritin destabilizing its structure. ROS formation originates from
a variety of cellular sources with improperly coordinated iron,
such as small LIP carrier molecules, the mutant FTL C-terminus,
protein proteolysis products, or unfolded or aggregated proteins.
Reductants such as ascorbate are clearly available in the brain and
the Haber-Weiss and Undenfriend-type reactions use ascorbate
and iron to generate various damaging ROS depending on
iron coordination. The process of protein aggregation, especially
with ferritin containing the mtFTL subunit unraveled C-termini,
will sample a variety of conformations as the initial aggregates
are formed. It follows that iron, especially but not necessarily
in great excess, could sample a variety of coordinations with
some being facile ROS producers, and this sampling would likely
occur not only with ferritin and HF but with other proteins
and neurodegenerative diseases. Interestingly, the finding that HF
and HF models produce a substantial fraction of SDS-insoluble
ferritin brings up the possibility that the IBs, once formed, could
hinder penetration of a reductant as large as ascorbate from their
interior and keep iron safely six coordinate and oxidized. ROS
generation on the surface of the IBs may occur, but the surface
area to volume ratio would suggest a net reduction in damage by
IB mutant ferritin over what would occur with small dispersed
mutant ferritin aggregates and iron. The proteasome may target
more than mutant ferritin alone, including repair or removal of
other ROS-damaged proteins. However, IB buildup, transport
and elimination is another issue.
On the negative side, the size and number of IBs increase with
age, and formation of a large number of IBs would likely hinder
crucial cytoplasmic transport or nuclear processes. Non-mutant
ferritin aggregates are known to associate with tubulin (Hasan
et al., 2006) and ferritin associates with kinesin (Jang et al., 2016),
suggesting the mutant ferritin aggregates could be problematic in
cytoskeletal transport disruption in that transport requires these
proteins. Disruption of transport would scale with the age of the
cells, and not only hinder ferritinophagy, but a number of other
crucial cellular transport processes. Thus, damage could occur in
a cyclical manner through inhibition of required ongoing cellular
processes involving transport and clearance.
The overall pathway in HF from mutant ferritin expression to
cellular dysfunction and death is a long-term stressful process.
The gradual nature of HF development suggest that cells do
cope with ferritin overexpression and elevated iron for some
time before becoming critically dysfunctional. Increased iron in
the LIP leads to ROS production and overproduction of ferritin
with elimination of ferritin compromised (Figure 6a). These two
misfunctions lead to a more general cellular dishomeostasis by
causing several stressors taxing the cells and diverting energy and
material away from bulk metabolism, transport, and repair. ROS
production is strongly associated with improperly coordinated
iron (Figure 6b) which can become more numerous as the
ferritin mutant, is aggregates, and other misfolded proteins
and their aggregates accumulate and provide iron-binding sites.
Cells expend synthesis energy to eliminate ROS and repair
damage. The increases in iron and lipid damage, which are
known markers for ferroptosis, are clearly observed in HF, but
the moderate increase in iron levels and gradual, cumulative
nature of the overall damage suggests a more general, long term,
cellular dishomeostasis. Still, the moderately elevated iron and
ROS lipid damage, modified by the gradual, cumulative cellular
dishomeostasis, may produce a long term ferroptotic-like state
(Figure 6c). It is worth mentioning a cautionary note that many
in vivo and in vitro studies of iron homeostasis and cellular
stress are made (1) under conditions of chelator, reductant, and
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ROS concentrations and (2) over time scales that are designed
to elicit a change that mimics some aspect of a disease state.
However, these studies may be unrepresentative of the low
physiological concentrations and long time course of the disease
under investigation, especially if it takes years to develop such as
with most neurodegenerative diseases.
This review on HF details biochemical aspects of metal ion
interactions, protein misbehavior, and cellular responses that
may have parallels or commonality to other neurodegenerative
diseases, especially with respect to ROS formation and damage,
as well as protein aggregation, inclusion formation, and disposal
pathway inhibition. With respect to HF treatment, we can
add two additional approach to our previous suggestion
of simultaneous administration of a radical scavenger and
appropriate iron ion chelator (Muhoberac and Vidal, 2013).
Importantly, Ftl−/− mice show that because FTH1 ferritin
homopolymers can maintain brain iron homeostasis in a mouse
model, there is the potential for development of a therapeutic
approach for HF treatment using RNA interference to induce
sequence-specific post-transcriptional gene silencing of mutant
FTL or alternatively both, wild-type and mutant FTL alleles
(Li et al., 2015). In addition, drug-based manipulation or
enhancement at some level of the cellular disposal mechanisms
may reduce ongoing ferritin and aggregate accumulation, and
thus reduce cellular stress enhancing survival. It is hoped that
researchers in the field of neurodegeneration will be able to find
parallels and apply them to their individual systems of study and
lead to more robust treatments.
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